Jian Lin

This inventor holds 48 USPTO granted patents and 17 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Cancer Therapeutics. Top assignees: Forma Therapeutics, Inc., Forma Tm, LLC, Genentech, Inc.. Active years: 2005-2026.

USPTO Granted Patents = 48 (Patent Applications = 17)

% Patents Active = 56.3

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 8.3

ph-index = 15

Forward Citations = 1,048(Granted Patents)

Location History:

Sunnyvale, CA (US) (2005)
Walpole, MA (US) (2007 - 2011)
Watertown, MA (US) (2017)
Watertown, CA (US) (2020)
Acton, MA (US) (2008 - 2024)

Company Filing History:

20 out of 125

Forma Therapeutics, Inc.

Epix Pharmaceuticals, Inc.

Casma Therapeutics, Inc.

Novo Nordisk Healthcare Ag

patents

13. 3 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

NAMPT Inhibitors

Isocitrate Dehydrogenase

Purinones

Quinolinone Derivatives

Pyridin-2(1H)-one

Ubiquitin-Specific Protease

Fused-Bicyclic Compounds

Piperidine Derivatives

Cancer Treatment

Compositions

Compounds

Carboxamide Compounds

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698266 - TRPML modulators (2026-08-04),

2. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

3. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

4. 12122778 - Activating pyruvate kinase R (2024-10-22),

5. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors (2024-07-23),

6. 11566013 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1) (2023-01-31),

7. 11547701 - Compounds and compositions for the inhibition of NAMPT (2023-01-10),

8. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

9. 11479564 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) (2022-10-25),

10. 11279687 - Compounds and compositions for the inhibition of NAMPT (2022-03-22),

11. 11161848 - Purinones as ubiquitin-specific protease 1 inhibitors (2021-11-02),

12. 10889567 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2021-01-12),

13. 10807976 - Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors (2020-10-20),

14. 10772874 - Compounds and compositions for the inhibition of NAMPT (2020-09-15),

15. 10696692 - Amido-benzyl sulfone and sulfoxide derivates (2020-06-30),

Title: The Innovative Journey of Jian Lin

Introduction: Jian Lin, a talented inventor hailing from Acton, MA (US), has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Jian Lin's latest patents showcase his prowess in the field of technology, with a focus on advancements in artificial intelligence, renewable energy, and sustainable materials.

Career Highlights: Throughout his illustrious career, Jian Lin has been at the forefront of technological innovation. His work has revolutionized various industries, including healthcare, transportation, and communication.

Collaborations: Jian Lin has collaborated with leading research institutions, universities, and tech companies to further his inventions. His partnerships have led to the development of cutting-edge technologies that have had a lasting impact on society.

Conclusion: Jian Lin's dedication to pushing the boundaries of innovation and his passion for creating a better future through technology make him a true visionary in the world of inventors.